苑东生物：全资子公司盐酸乙哌立松片获得药品注册证书

Core Viewpoint - Yuan Dong Biotech (688513.SH) announced that its wholly-owned subsidiary, Shuo De Pharmaceutical, has received the drug registration certificate from the National Medical Products Administration for the drug Etifoxine Hydrochloride Tablets, which is expected to generate approximately 103 million yuan in sales in 2024, reflecting a year-on-year growth of 14.01% [1] Company Summary - The drug Etifoxine Hydrochloride Tablets, with a specification of 50mg, is classified as a Class 4 chemical drug and is indicated for improving muscle tension states associated with conditions such as cervical spondylosis, shoulder periarthritis, and low back pain [1] - The drug was originally developed by Japan's Eisai Co., Ltd. and was first approved for sale in Japan in 1983 [1] - The approval of this drug is considered equivalent to passing the consistency evaluation, and it is not expected to have a significant impact on the company's recent performance [1] Industry Summary - The projected sales figure of approximately 103 million yuan for 2024 indicates a positive growth trajectory for the drug within the market, suggesting a healthy demand for treatments addressing muscle tension related to common musculoskeletal disorders [1]